CPA
ADVM

Capital Performance Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Capital Performance Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-116
Closed -$814 – 215
2024
Q3 		$814 Buy
+116
New +$842 ﹤0.01% 2014

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Performance Advisors's ADVM Position: Q4 2024 in Review

Capital Performance Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2024, closing a stake of 116 shares — an estimated $814 sold.

Capital Performance Advisors first reported a position in ADVM in Q3 2024 and held it in 1 quarter. The position peaked at $814 in Q3 2024. 69 funds tracked by Wall St. Rank hold ADVM as of Q4 2024.

  • Capital Performance Advisors reported no remaining Adverum Biotechnologies position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 116 Adverum Biotechnologies shares in Q4 2024, an estimated $814.
  • Capital Performance Advisors first reported a position in Adverum Biotechnologies in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Adverum Biotechnologies position peaked at $814 in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.